An appropriate example is the transferrin-based NPs that have elicited tremendous abilities to cross the BBB/BBTB by targeting the transferrin receptor-mediated transcytosis (see also Section 4.4.1) for brain tumor therapy [163,164]. This evidence concerns the gene TFRC and brain neoplasm.